The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for ...

The JAK2 gene mutation discovery led to JAK inhibitors, transforming myelofibrosis treatment by targeting the JAK-STAT pathway. Four FDA-approved JAK inhibitors for myelofibrosis include Jakafi, ...

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed. Disease-free ...

Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...